de-escalation
People and trials concerned with giving less treatment where it is safe to do so. 17 records carry it: 16 people, 1 trial.
Related tags
17 records
| Cancers | Other tags | ||||
|---|---|---|---|---|---|
Aleix Prat Head of Medical Oncology, Hospital Clínic de Barcelona; Scientific Director, SOLTI · Hospital Clínic de Barcelona / IDIBAPS Translational oncologist who built genomic tests (HER2DX) to decide which HER2-positive patients can skip chemotherapy. | HER2-positive breast cancer, HR-positive / HER2-negative breast cancer | none | breast, genomics | ||
Andreas Engert Professor of Internal Medicine, Hematology and Oncology, University Hospital Cologne; former Chair, German Hodgkin Study Group · Uniklinik Köln (CIO) Led the GHSG for two decades, running the HD10 to HD18 trials that cure over 90% of Hodgkin lymphoma with less treatment. | Hodgkin lymphoma | none | hodgkin, ghsg | ||
Armando E. Giuliano Executive Vice Chair of Surgery, Cedars-Sinai Medical Center · Cedars-Sinai Cancer Brought sentinel node biopsy to breast cancer and led ACOSOG Z0011, which ended routine axillary dissection for many women. | HR-positive / HER2-negative breast cancer | none | breast, surgery | ||
Charlotte E. Coles Professor of Breast Cancer Clinical Oncology, University of Cambridge; Consultant, Addenbrooke's Hospital · Cancer Research UK Cambridge Centre / CRUK Cambridge Institute Led IMPORT LOW, which showed partial-breast radiotherapy is as effective as whole-breast treatment with fewer side effects. | HR-positive / HER2-negative breast cancer | none | radiotherapy, breast | ||
COG ACNS0331 NCT00085735 This trial asked whether children with average-risk medulloblastoma could safely receive less radiation. Shrinking the boost to the tumour bed was safe; cutting the dose to the whole brain and spine in young children was not, so 23.4 Gy remains the floor for most. | Medulloblastoma, WNT-activated medulloblastoma, Group 3 and group 4 medulloblastoma | paediatric, cns | |||
E. Shelley Hwang Breast surgical oncologist, Duke Cancer Institute · Duke Cancer Institute Duke surgeon who led COMET, the trial testing whether women with low-risk DCIS can safely be monitored instead of having surgery straight away. | Ductal carcinoma in situ, Breast cancer | none | breast, surgery, trialist | ||
Helena Earl Emeritus Professor of Clinical Cancer Medicine, University of Cambridge · Cancer Research UK Cambridge Centre / CRUK Cambridge Institute Led PERSEPHONE, which showed six months of trastuzumab is nearly as good as twelve for most patients. | HER2-positive breast cancer | none | breast, her2 | ||
Hisham Mehanna Professor of Head and Neck Surgery and Director, Institute of Head and Neck Studies and Education, University of Birmingham · University Hospitals Birmingham / University of Birmingham Cancer Research Centre Surgeon who led De-ESCALaTE and PET-NECK, two trials that changed how HPV-positive throat cancer is treated and followed up. | Head and neck squamous cell carcinoma | none | head-and-neck, surgery, uk | ||
Jeanne Tie Medical Oncologist, Peter MacCallum Cancer Centre; Laboratory Head, Walter and Eliza Hall Institute · Walter and Eliza Hall Institute of Medical Research Led DYNAMIC, the first randomised trial to show ctDNA can safely guide who needs chemotherapy after colon cancer surgery. | Colorectal cancer | none | ctdna, colorectal | ||
Joseph A. Sparano Chief, Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai · The Mount Sinai Hospital / Tisch Cancer Institute Led TAILORx, which showed most women with intermediate Oncotype scores can safely skip chemotherapy. | HR-positive / HER2-negative breast cancer | none | breast, ecog-acrin | ||
Kevin Kalinsky Director, Glenn Family Breast Center, Winship Cancer Institute of Emory University · Winship Cancer Institute of Emory University Led RxPONDER, which showed postmenopausal women with 1-3 positive nodes and low recurrence scores do not need chemotherapy. | HR-positive / HER2-negative breast cancer | none | breast, swog | ||
Marie Plante Gynaecologic oncologist, CHU de Québec - Université Laval · CHU de Québec - Université Laval Quebec surgeon who pioneered fertility-sparing surgery for cervical cancer and led SHAPE, the trial that showed a simple hysterectomy is enough for low-risk early cervical cancer. | Early cervical cancer and fertility-sparing surgery, Cervical cancer | none | cervical, surgery, trialist | ||
Mark B. Faries Co-Director, Melanoma Program, The Angeles Clinic and Research Institute, Cedars-Sinai · Cedars-Sinai Cancer Surgeon who led MSLT-II, showing that removing all lymph nodes after a positive sentinel node does not improve melanoma survival. | Melanoma | none | melanoma, surgery | ||
Martin Schlumberger Emeritus Professor of Oncology, Gustave Roussy and Université Paris-Saclay · Gustave Roussy Led SELECT (lenvatinib) and the ESTIMABL trials that showed many thyroid cancer patients can have lower radioiodine doses or none at all. | Thyroid cancer | none | thyroid, radioiodine | ||
Maura L. Gillison Professor of Thoracic/Head and Neck Medical Oncology, MD Anderson Cancer Center · MD Anderson Cancer Center Established that HPV causes a distinct, better-prognosis form of throat cancer and led RTOG 1016 on how to treat it. | Head and neck squamous cell carcinoma | none | head-and-neck, hpv | ||
Monica Morrow Chief, Breast Service, Department of Surgery, Memorial Sloan Kettering Cancer Center · Memorial Sloan Kettering Cancer Center Breast surgeon whose margin and axillary guidelines cut unnecessary re-excisions and lymph node surgery worldwide. | HR-positive / HER2-negative breast cancer, Triple-negative breast cancer, HER2-positive breast cancer | none | breast, surgery | ||
Nadia Harbeck Head of the Breast Center, LMU University Hospital Munich; Chair, West German Study Group · LMU Klinikum München German breast oncologist whose ADAPT trials use biology to decide who can have less chemotherapy. | HR-positive / HER2-negative breast cancer, HER2-positive breast cancer | none | breast, guidelines |
